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y-Aminolevulinic acid (ALA), precursor of heme, accumulates in a number of organs, particularly in liver of patients with acute
porphyrias or lead intoxication. This study characterizes the involvement of bilirubin as an antioxidant in a chronic intoxication with ALA.
Female Wistar rats were injected intraperitoneally a daily dose of 40 mg ALA/body wt., during 10 days. A marked increase in lipid
peroxidation and a decrease in GSH content were observed 24 h after the last injection of ALA. The activities of liver antioxidant enzymes,
superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase were also diminished. ALA synthase (ALA-S) and heme
oxygenase-1 were induced. Both ALA dehydratase (ALA-D) and porphobilinogenase (PBG-ase) activities were inhibited. Administration of
bilirubin (5 mmol/kg body wt.) 2 h before ALA treatment entirely prevented the effects of ALA. Co-administration of ALA and Sn-
protoporphyrin IX (Sn-PPIX; 100 Ag/body wt., i.p.), a potent inhibitor of heme oxygenase, completely abolished its induction and provoked a
marked decrease in liver GSH levels as well as an increase in lipid peroxidation. These results add further support to the proposal assigning
bilirubin a key protective role against oxidative damage here induced by ALA.D 2003 Elsevier Science B.V. All rights reserved.Keywords: Bilirubin; y-aminolevulinic acid; Heme oxygenase-1; Oxidative stress; Antioxidant enzyme1. Introduction
Acute intermittent porphyria (AIP), one of the three acute
porphyrias, is a dominant inherited metabolic disorder of
heme biosynthesis. It is caused by a primary genetic defect
in the enzyme porphobilinogen-deaminase (PBG-D; EC
4.3.1.8), which leads to accumulation and increased urinary
excretion of the precursors y-aminolevulinic acid (ALA) and
porphobilinogen (PBG) [1].0925-4439/03/$ - see front matter D 2003 Elsevier Science B.V. All rights reserv
doi:10.1016/S0925-4439(03)00081-4
Abbreviations: ALA, y-aminolevulinic acid; ALA-D, y-aminolevulinic
acid dehydratase; ALA-S, y-aminolevulinic acid synthase; AIP, acute
intermittent porphyria; CAT, Catalase; DTNB, 5,5V dithio-bis-(2-nitro-
benzoic acid); GSH-Px, glutathione peroxidase; HO-1, Heme oxygenase
isoform 1; HO-2, Heme oxygenase isoform 2; PBG, porphobilinogen;
PBG-ase, porphobilinogenase; ROS, reactive oxygen species; Sn-PPIX, Sn-
protoporphyrin IX; SOD, superoxide dismutase; TBARS, thiobarbituric
acid reactive substances
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3645.
E-mail address: ptomaro@ffyb.uba.ar (M.L. Tomaro).The acute porphyrias are characterized by attacks of
neuropsychiatric symptoms, which may be due to toxic
levels of ALA, or a consequence of a deficit of vital heme
proteins resulting from impaired synthesis of heme or both.
Reactive oxygen species (ROS) are involved in the patho-
physiology of AIP [2].
ALA undergoes enolization and further metal-catalyzed
aerobic oxidation at physiological pH to yield superoxide
radical (O2
.), hydrogen peroxide (H2O2) and hydroxyl radical.
(HO.). Therefore, accumulation of ALA in AIP patients
might endogenously enhance ROS levels leading to oxidative
stress.
Heme oxygenase (HO), the rate-limiting enzyme in
heme degradation pathway, is induced in animal tissues,
particularly in liver by many factors including its own
substrate heme, several heme-proteins, heavy metals,
UVA radiation, hypoxia, hyperoxia and others [3–6].
Induction of HO is entirely prevented by administration
of several antioxidants such as a-tocopherol and allopu-
rinol [6]. In recent years, good evidence has been
accumulated showing that bilirubin can act as a highlyed.
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been proposed that it can play a physiological and key
role as an endogenous protective agent against oxidant
mediated injury [7–11].
Antioxidant effects suggest that oxidant species play a
major part in the induction of HO either directly or by
GSH depletion [6,8,12]. An increase in HO activity will
enhance bilirubin formation and because unconjugated
bilirubin is an efficient scavenger of ROS, its increase
would be the cellular response to oxidative stress [8,12–
14].
Of the two known mammal liver HO isoenzymes, HO-1
and HO-2, only HO-1 is inducible; here we will only refer to
HO-1.
The aim of this work has been to investigate the effect of
the administration of bilirubin on the oxidative damage
induced by a chronic intoxication of ALA in rat liver.2. Materials and methods
2.1. Materials
ALA and Sn-protoporphyrin IX (Sn-PPIX) were pur-
chased from Porphyrin Products (Logan, UT). GSH, GSSG,
5,5Vdithio-bis-(2-nitrobenzoic acid) (DTNB), thiobarbituric
acid, glutathione reductase, bilirubin, PBG and Triton X-
100 were from Sigma Chemical Co. (St. Louis, MO), tert-
butyl hydroperoxide was from Aldrich Chemical (Phillips-
burg, NJ). All other chemicals were of analytical grade.
2.2. Animals
Female Wistar rats (120–150 g) were maintained on
food and water ad libitum and housed under conditions of
controlled temperature (25F 2 jC) and illumination (12
h light–dark cycle; light from 07:00 to 19:00 h). Animals
were fasted for at least 16 h before experiment.
2.2.1. Drug solutions
ALAwas dissolved in saline, and the pH was adjusted to
7.4 with phosphate buffer. Bilirubin and Sn-PPIX were
prepared as follows: solutions in 0.1 M NaOH were freshly
prepared before administration, adjusted to pH 7.4 with
phosphate buffer and diluted with saline.
2.2.2. Treatment
ALA-group: rats were injected intraperitoneally (i.p.)
with a daily dose of ALA (40 mg/body wt.), during 10 days.
In the Bilirubin–ALA group, animals were i.p. injected with
bilirubin (5 Amol/kg body wt.), 2 h before the treatment with
ALA. Control groups received either saline solution (Control
group) or bilirubin alone (Bilirubin group). When Sn-PPIX
was used, rats were injected i.p. (100 Amol/kg body wt.)
simultaneously with the last ALA injection. Animals were
treated in accordance with guidelines established by theAnimal Care and Use Committee of the Argentine Associ-
ation of Specialists in Laboratory Animals (AADEALC),
and were in accordance with the Guide to the Care and Use
of Experimental Animals published by the Argentine Coun-
cil on Animal Care.
2.3. Enzyme preparations and assays
Rats were anesthetized with sodium pentobarbital (50
mg/kg body weight, i.p.) and killed 24 h after the last
ALA injection. A fraction of the liver (approximately one-
third) was excised and immediately homogenized (1:3 w/v)
in a solution containing 0.9% NaCl, 0.1 mM/Tris–HCl pH
7.4, 0.5 mM/EDTA, for ALA synthase (ALA-S) determi-
nation [15]. The remainder of the organ, previously per-
fused with ice-cold saline solution, was removed and
homogenized in a Potter–Elvehejm homogenizer using
different solutions. For HO assay, homogenate preparation
and enzyme activity determination were performed accord-
ing to Llesuy and Tomaro [7]. Microsomal HO-1 was
obtained as described elsewhere [16]. To determine cata-
lase (CAT), total superoxide dismutase (SOD) and gluta-
thione peroxidase (GSH-Px) activities, liver homogenates
were prepared in a solution containing 140 mM KCl and
25 mM potassium phosphate buffer (pH 7.4), then centri-
fuged at 600 g for 10 min. The resulting supernatant, a
suspension of preserved organelles, was used for measur-
ing the enzyme activities. CAT activity was determined by
recording the decrease in absorbance at 240 nm [17],
GSH-Px following NADPH oxidation at 340 nm [18]
and SOD by inhibition of adenochrome formation rate at
480 nm [19]. ALA dehydratase (ALA-D) activity was
determined according to Batlle et al. [20] and porphobili-
nogenase (PBG-ase) activity following the method of
Rimington [21].
2.4. Lipid peroxidation
Lipid peroxidation in liver was determined by measuring
the rate of production of thiobarbituric acid reactive sub-
stances (TBARS), expressed as malondialdehyde equiva-
lents [22]. One volume of homogenate was mixed with 0.5-
volume TCA (15% w/v) and centrifuged at 2000 g for 10
min. The supernatant (1 ml) was mixed with 0.5-ml thio-
barbituric acid (0.7% w/v) and boiled for 10 min. After
cooling, sample absorbance was read spectrophotometrical-
ly at 535 nm. Malondialdehyde concentration was calculat-
ed using a e value of 1.56 105 M 1cm 1.
2.5. Endogenous hepatic GSH content
Total glutathione (GSH plus GSSG) was determined in
liver homogenates after precipitation with 2% perchloric,
and using yeast-glutathione reductase, DTNB and NADPH
and reading at 340 nm. GSSG was determined by the same
method in the presence of 2-vinylpyridine. GSH was
Table 1
Effect of ALA and bilirubin on antioxidant enzyme activities
Group Catalase
(pmol/mg
protein)
Total
superoxide
dismutase
(U/mg protein)a
Glutathione
peroxidase
(U/mg protein)b
Control 10.5F 1.1 9.0F 0.2 0.130F 0.004
Bilirubin 10.7F 0.9 10.8F 0.1* 0.135F 0.006
ALA 5.1F 0.5* 6.8F 0.1* 0.100F 0.004*
Bilirubin +ALA 9.4F 0.9 8.6F 0.2 0.131F 0.004
Enzymatic activities were assayed as described in the text.
a One unit of SOD activity is defined as the amount of enzyme required
to inhibit 50% of epinephrine autoxidation.
b One unit of the enzyme represents the decrease of 1 mmol NADPH/
min under the assay conditions.
*Significant differences as assessed by Student’s t test.
Fig. 1. Effect of ALA and bilirubin on lipid peroxidation. Rats were
treated as described in Materials and methods. Values are the means
of three different experiments using three rats each time, and bars
indicate S.E. *Significant differences ( P < 0.05) as assessed by Student’s
t test.
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and GSSG [23].
2.6. Protein determination
Protein concentration was measured following Lowry et
al. [24] using bovine serum albumin as standard.
2.7. Statistics
Values expressed in figures and tables are the means of
three different experiments, using at least three animals in
each point and run in duplicate and they indicate mean
valuesF S.E. Differences between control and treated ani-Fig. 2. Effect of ALA and bilirubin on GSH liver content. Rats were
treated as described in Materials and methods. Values are the means
of three different experiments using three rats each time, and bars
indicate S.E. *Significant differences ( P < 0.05) as assessed by Student’s
t test.mals were analyzed using Student’s t test, taking P < 0.05 as
significant.3. Results
3.1. Oxidative stress generation
ROS are responsible for peroxidative cell damage.
TBARS were 60% increased 24 h after the last ALA
injection (Fig. 1).
GSH is a leading substrate for enzymatic antioxidant
functions and is also a known radical scavenger. Therefore,
if ALA is inducing the formation of ROS, we would expect
GSH levels to be affected, and we can see in Fig. 2 that in
the liver of animals receiving ALA, GSH concentration was
about 35% decreased when compared to control animals.
When rats were pretreated with bilirubin, both TBARS
and GSH levels were equal to controls and treatment with
bilirubin alone did not have any effect on any of these
parameters (Figs. 1 and 2).
These findings are clearly showing that a chronic intox-
ication with ALA induced oxidative stress in rat liver and
that bilirubin pretreatment entirely prevented this action.
3.2. Enzymatic defense system
Table 1 shows the activities of CAT, SOD and GSH-Px in
the liver of animals treated with ALA and bilirubin as wellTable 2
In vitro effect of different concentrations of bilirubin on SOD activity
Bilirubin (mM) Superoxide dismutase
(U/mg protein)
0 9.0F 0.5
0.05 8.7F 0.6
0.1 9.4F 0.5
0.5 9.1F 0.6
Enzyme activity was assayed as described in the text. One unit in the SOD
assay is defined as the amount of enzyme required to inhibit 50% of
epinephrine autoxidation.
Table 3
Effect of ALA and bilirubin on heme biosynthesis enzyme activities
Group ALA-S
(U/mg protein)a
ALA-D
(U/mg protein)b
PBG-ase
(U/mg protein)c
Control 0.11F 0.01 6.9F 0.2 0.030F 0.001
Bilirubin 0.10F 0.01 7.0F 0.1 0.029F 0.003
ALA 0.14F 0.01* 3.7F 0.1* 0.019F 0.002*
Bilirubin +ALA 0.10F 0.01 7.1F 0.2 0.030F 0.003
Enzymatic activities were assayed as described in the text.
a One unit of the enzyme forms 1 nmol ALA/60 min under assay
conditions.
b One unit of the enzyme forms 1 nmol PBG/60 min under the assay
conditions.
c One unit of the enzyme forms 1 nmol uroporphyrin/60 min under the
assay conditions.
*Significant differences as assessed by Student’s t test.
Table 4
Effect of Sn-PPIX administration on the HO-1 induction and on TBARS
and GSH contents in ALA-treated rat livers
Treatment HO-1
(U/mg protein)a
TBARS
(nmol/min/
mg protein)
GSH content
(Amol/g liver)a
Control 0.50F 0.01 0.10F 0.01 7.5F 0.2
ALA 0.80F 0.02* 0.16F 0.01* 5.0F 0.1*
Sn-PPIX 0.25F 0.01* 0.11F 0.01 7.2F 0.3
Sn-PPIX+ALA 0.45F 0.04 0.22F 0.02* 4.4F 0.2*
ALA and Sn-PPIX were administered as described in Materials and
methods. Control animals were injected with saline solution. Enzymatic
activity was assayed as described in the text.
a One unit of the enzyme forms 1 nmol bilirubin/30 min under assay
conditions.
*Significant differences as assessed by Student’s t test.
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enzymes are significantly inhibited (CAT 51%, SOD 25%
and GSH-Px 23%) 24 h after the last ALA injection.
Surprisingly, in the bilirubin-treated control group, we have
found an enhancement of about 20% in SOD activity. To
determine whether bilirubin itself could exert any action on
SOD, its activity was measured in vitro in the presence of
different bilirubin concentrations. As illustrated in Table 2,
bilirubin concentrations here used have no effect on SOD
activity.
3.3. Heme biosynthesis enzymes
To confirm the antioxidant protective properties of bili-
rubin on proteins, its effect on three enzymes of the
porphyrin pathway was investigated (Table 3). Administra-
tion of ALA enhanced ALA-S activity by 40%, while ALA-
D and PBG-ase activities were 47% and 37% inhibited,
respectively. We can also observe that ALA-D and PBG-ase
inhibition occurs concomitantly to GSH depletion (Table 3Fig. 3. Effect of ALA and bilirubin on HO-1 activity. Rats were treated as
described in Materials and methods. One unit of HO-1 is defined as the
amount of enzyme producing 1 nmol bilirubin/30 min under the standard
incubation conditions. Values are the means of three different experiments
using three rats each time, and bars indicate S.E. *Significant differences
( P< 0.05) as assessed by Student’s t test.and Fig. 2). Pretreatment with bilirubin totally prevented the
effects of ALA on these enzymes.
3.4. Heme oxygenase activity
As shown in Fig. 3, ALA injection increased liver HO-1
activity by 60%. Bilirubin alone had not any effect, but
bilirubin pretreatment completely prevented HO-1 induction
provoked by chronic ALA administration.
Previous results using acute intoxication models with
different drugs have demonstrated that as a consequence of
ROS production, liver GSH levels rapidly decreased and
then HO-1 was induced. It was also observed that HO-1
induction appeared to occur once the ROS have increased
and the antioxidant defense system has decreased. Bilirubin
action as a protective agent against oxidative stress suggests
that inhibition of HO-1 could enhance even more the
oxidative stress induced by ALA. Therefore, the effect of
Sn-PPIX, a strong inhibitor of HO-1, was assayed when
being administered simultaneously and together with ALA
in the last injection of the ALA treatment. Table 4 shows
that a single administration of Sn-PPIX decrease HO-1
activity to half. Simultaneous administration of both the
inducer and the inhibitor of HO-1 slightly decreased hepatic
GSH levels (12%) and significantly increased TBARS
production (37%) over the values obtained using ALA
alone.4. Discussion
Aerobic organisms are continuously exposed to oxygen,
which renders them prone to damage generated by ROS.
There are a number of cellular mechanisms to protect the
cell from oxidative stress. Antioxidant enzymes such as
CAT, SOD and GSH-Px play critical roles in oxidative stress
protection by converting ROS into less harmful products
[25,26]. Recently, HO-1 and its product bilirubin have
gained attention in cytoprotection against oxidant-mediated
injury [7,9–11,27,28].
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poisoning) and inborn porphyrias (e.g., AIP) [1]. Endoge-
nous production of ROS has been postulated as the main
cause in many aging-related pathologies such as cancer, and
a correlation between AIP and hepatoma formation was
reported in symptomatic patients [29]. Several reports have
demonstrated the involvement of ROS in the pathophysiol-
ogy of AIP, where ALA undergoes enolization and further
iron-catalyzed oxidation, leading to the production of su-
peroxide radicals (O2
 ), hydrogen peroxide (H2O2) and
hydroxyl radical (HO.) [30]. Consequently, overproduction
and accumulation of ALA is an endogenous source of ROS,
and chronically enhanced levels of ALA in AIP patients
could play an important role in induction of DNA damage
[31]. There are several antioxidants known to protect against
chemical oxidative damage. Recently, Karbownik et al.
[32,33] studied the antioxidant and anticarcinogenic activ-
ities of melatonin in ALA-treated rats, while Princ et al.
[34,35] had previously demonstrated the antioxidant protec-
tion of melatonin against ALA-induced oxidative damage in
rat cerebral cortex and cerebellum.
Our data show now that administration of bilirubin to rats
reduces ALA-induced lipid peroxidation, restores GSH
content and the activities of the antioxidant enzymatic
system to normal levels, providing further evidence for the
proposal that bilirubin can act as an efficient antioxidant and
free radical scavenger (Figs. 1 and 2, Table 1). Besides, in
vivo bilirubin administration increases SOD activity. Taking
together these results and the fact that bilirubin by itself does
not affect SOD activity in vitro (Table 2), it could be
inferred that bilirubin would be stimulating SOD overex-
pression.
The general antioxidant protective properties of bilirubin
on proteins were further investigated by studying its action
on three heme biosynthesis enzymes. In ALA-treated rats
ALA-S activity was enhanced, whereas ALA-D and PBG-
ase were inhibited (Table 3). ALA-S activity is normally
very low, but this enzyme rapidly responds to cellular
requirements for heme. Heme is rapidly catabolized because
of HO-1 induction. On the other hand, heme is the pros-
thetic group of many heme proteins such as cytochromes,
CAT and peroxidases and some of these are involved in the
antioxidant cellular defense system [36]. It is widely ac-
cepted that the hepatocellular free heme pool controls the
activity of the rate-limiting enzyme ALA-S through feed-
back and repressing regulatory mechanisms [37]. Therefore,
if a diminution of the intracellular heme pool due to either
increased heme catabolism, decreased heme synthesis or
enhanced heme proteins synthesis occurs, ALA-S activity
should be increased. ALA-D is a thiol enzyme and its
activity can be stimulated in vitro by GSH and other thiol
derivatives [38]. PBG-ase is also a thiol enzyme, but its
sulfydryl groups are situated in nonexposed regions [39].
Nonetheless, inhibition of activity could be attributed to
ROS-induced modifications of proteins, such as fragmenta-
tion, increased susceptibility to proteolysis and cross-linkingreactions [40]. Bilirubin totally prevented the decrease of
antioxidant enzymes activities and induction of HO-1 ac-
tivity provoked by ALA treatment (Table 3, Fig. 3). These
findings are in agreement with our own previous reports on
the protective effect of bilirubin against oxidative stress
caused by different physical and chemical agents [28 and
references herein].
Administration of Sn-PPIX, a known competitive inhib-
itor of HO-1, expectedly decreased HO-1 activity [41]
(Table 4). When the inhibitor was given together with the
inducer ALA, HO-1 activity remained at control levels, but
an increase in TBARS content and a decrease in GSH levels
were observed (Table 4).
In conclusion, our data show that ROS generation by
ALA alters both heme biosynthesis and degradation. They
also demonstrate that the cell possesses an inducible path-
way against oxidative stress finally leading to increased
bilirubin formation, which then exerts its antioxidant pro-
tective action.
These results shed light on the response of both heme
biosynthesis and degradation to ALA-induced oxidative
stress, and further support the involvement of bilirubin as
a physiological protective agent against ALA-induced oxi-
dative cell injury. The potential use of bilirubin as an
antioxidant in combination with other antioxidants or with
conventional treatments, as a new therapeutic approach for
acute porphyrias patients, can be considered.Acknowledgements
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